Cancer Conference Update 3 | 2007

Breast Cancer


	Kathy D Miller, MD Sheila D Ward Scholar of Medicine Associate Professor of Medicine Department of Hematology/Oncology Indiana University School of Medicine Indianapolis, Indiana Click here to download the entire interview		MP3

Track 1

ECOG-E1199: Adjuvant AC followed by paclitaxel or docetaxel weekly or every three weeks

Track 2

NCIC-CTG-MA21: CEF versus dose-dense EC

paclitaxel versus AC

paclitaxel in node-positive or
high-risk node-negative breast cancer

Track 3

Adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer

Track 4

Paclitaxel with or without lapatinib as first-line therapy for metastatic breast cancer (mBC)

Track 5

Safety and efficacy of capecitabine with bevacizumab as first-line therapy for mBC

Track 6

Weekly or every three-week nanoparticle albumin-bound (nab) paclitaxel compared to every three-week docetaxel as first-line therapy for mBC

Track 7

Nab paclitaxel with capecitabine in first-line treatment of mBC

Track 8

Three dosing schedules of nab paclitaxel with bevacizumab as first-line therapy for HER2- negative mBC

Track 9

A novel capecitabine schedule based on Norton-Simon mathematical modeling

Track 10

Molecular pathways, gene ontology categories and response to chemotherapy with bevacizumab in inflammatory and LABC


	Eric P Winer, MD Director, Breast Oncology Center Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Click here to download the entire interview		MP3

Track 1

Updated results of NCCTG-N9831 and NSABP-B-31: Adjuvant chemotherapy with trastuzumab in HER2-positive breast cancer

Track 2

Central testing for HER2 in NSABP-B-31 and benefit from adjuvant trastuzumab

Track 3

Five-year update of cardiac dysfunction in NSABP-B-31

Track 4

Cardiac safety of lapatinib and trastuzumab in mBC

Track 5

Association of topoisomerase II-alpha with responsiveness to anthracycline-based chemotherapy

Track 6

Prediction of Oncotype DX™ scores using standard prognostic criteria

Track 7

Impact of an Oncotype DX recurrence score on treatment decision-making

Track 8

Prognostic utility of the Oncotype DX assay in hormone receptor-positive, node-positive breast cancer —
Analysis of Intergroup Trial E2197

Track 9

Pertuzumab with trastuzumab in HER2-positive mBC after progression on trastuzumab

Track 10

BCIRG 007: Overall survival analysis of trastuzumab/ docetaxel with or without carboplatin as first-line therapy for HER2-amplified mBC

Track 11

Correlation of HER2 and chromosome 17 copy number with trastuzumab efficacy in CALGB-9840

Track 12

BCIRG 007: Serum HER2 levels in HER2-amplified mBC

Track 13

Cardiac events with trastuzumab and pertuzumab in HER2-positive mBC

Track 14

ECOG-E1100: Combined blockade of the HER receptor network in HER2-overexpressing mBC

Track 15

Activity of trastuzumab beyond disease progression in HER2-overexpressing mBC


	Stephen E Jones, MD Director, Breast Cancer Research Charles A Sammons Cancer Center Baylor University Medical Center Dallas, Texas Chair, US Oncology Breast Cancer Research Medical Director, US Oncology Research Houston, Texas Click here to download the entire interview		MP3

Track 1

Pharmacogenetics and tamoxifen: Hot flashes and breast cancer recurrence

Track 2

Pharmacogenomic testing and modeling analysis of benefit from tamoxifen versus the aromatase inhibitors in
early-stage breast cancer

Track 3

Time-dependent patterns of recurrence after early-stage breast cancer

Track 4

BIG 1-98: Cardiovascular adverse events with adjuvant letrozole or tamoxifen

Track 5

Central assessment of ER, PR and HER2 in BIG 1-98

Track 6

Meta-analysis of adjuvant aromatase inhibitor trials: Disease-free survival as a surrogate for overall survival

Track 7

Optimal use of adjuvant aromatase inhibitors: Up front or sequenced after tamoxifen?

Track 8

TEAM trial: Endometrial effects of exemestane compared to tamoxifen

Track 9

ARIBON: Effect of monthly oral ibandronate on adjuvant anastrozole-induced bone loss

Track 10

LEAP trial: Body mass index and bone turnover with letrozole, exemestane and anastrozole

Track 11

Risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy

Track 12

Discordance in ER, PR and HER2 between primary and metastatic breast cancer pathology samples

Track 13

Goserelin with anastrozole for premenopausal, hormone receptor-positive, recurrent or metastatic breast cancer

Track 14

Fulvestrant in the treatment of HER2-positive mBC

Track 15

Lipid-lowering effect of fulvestrant in hormone-sensitive mBC

Gastrointestinal Cancers


	Leonard B Saltz, MD Professor of Medicine Weill Medical College of Cornell University Attending Physician Colorectal Disease Management Team Leader Memorial Sloan-Kettering Cancer Center New York, New York Click here to download the entire interview		MP3

Track 1

Updated efficacy results of the MOSAIC trial: Oxaliplatin/5-FU/LV in adjuvant colon cancer

Track 2

Communicating with patients about adjuvant systemic therapy: A survey of 150 colorectal cancer survivors

Track 3

ACCENT data set: Survival after recurrence in patients with colon cancer that was treated with adjuvant therapy

Track 4

ACCENT data set: Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer

Track 5

CALGB-C89803: Impact of dietary patterns on cancer recurrence and survival among patients with Stage III colon cancer

Track 6

XELOX-1/NO16966: Bevacizumab in combination with XELOX or FOLFOX4 in first-line treatment for metastatic colorectal cancer

Track 7

XELOX-1/NO16966: A Phase III trial comparing XELOX to FOLFOX4 as first-line treatment for metastatic colorectal cancer

Track 8

BRiTE data set: Association between exposure to bevacizumab beyond first progression and overall survival

Track 9

CRYSTAL: A Phase III study of irinotecan and 5-FU/FA with or without cetuximab as first-line treatment for metastatic colorectal cancer

Track 10

OPUS: A randomized Phase II study of FOLFOX4 with or without cetuximab as first-line treatment for metastatic colorectal cancer

Track 11

OPTIMOX2: A randomized Phase II study of maintenance therapy versus chemotherapy-free intervals after FOLFOX in metastatic colorectal cancer

Track 12

Analysis of the effect of performance status on outcomes in trials of first-line treatment for metastatic colorectal cancer


	Alan P Venook, MD Professor of Clinical Medicine Associate Chief Division of Medical Oncology University of California, San Francisco San Francisco, California Click here to download the entire interview		MP3

Track 1

Meeting the 12 lymph node benchmark in colorectal cancer: A comparison of NCCN and SEER data

Track 2

EPOC (EORTC-40983): A Phase III study evaluating perioperative FOLFOX4 chemotherapy for patients with potentially resectable liver metastases

Track 3

Neoadjuvant chemotherapy including bevacizumab for patients with resectable liver metastases

Track 4

SHARP: A Phase III placebo-controlled trial evaluating sorafenib in advanced hepatocellular carcinoma

Track 5

Phase III trial of gemcitabine with bevacizumab versus gemcitabine with placebo in advanced pancreatic cancer

Track 6

SWOG-S0205: A Phase III study of gemcitabine with or without cetuximab in locally advanced or metastatic pancreatic adenocarcinoma

Track 7

Relationship of K-ras mutations and EGFR gene copy number to outcomes among patients with pancreatic cancer treated with erlotinib

Track 8

Clinical trials evaluating S-1 in advanced gastric cancer

Track 9

Phase II trial of cetuximab with weekly oxaliplatin/ 5-FU/FA in first-line treatment of metastatic gastric cancer

Track 10

FNLCC ACCORD07-FFCD 9703: Preoperative 5-FU/cisplatin versus surgery alone in adenocarcinoma of the stomach and lower esophagus

Track 11

Preoperative chemotherapy versus preoperative chemoradiation therapy in locally advanced esophagogastric adenocarcinomas

Track 12

Efficacy of sorafenib alone and in combination with chemotherapy in gastrointestinal malignancies

Track 13

Efficacy of adjuvant therapy in colorectal cancer

Track 14

Ongoing clinical trials in gastrointestinal cancer: Expectations for 2008

Track 15

Impact of sorafenib on survival in advanced hepatocellular carcinoma: Commentary by Dr Leonard Saltz

Gastrointestinal Cancers and Hematologic Malignancies


	Brad S Kahl, MD Assistant Professor of Medicine Director, Lymphoma Service University Hospital Madison, Wisconsin Click here to download the entire interview		MP3

Track 1

North American Intergroup Protocol C9710: Consolidation with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia

Track 2

Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide and rituximab as initial therapy for CLL

Track 3

CA180-034: Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with chronic-phase CML resistant or intolerant to imatinib

Track 4

Use of dasatinib in patients with previously untreated CML in chronic phase

Track 5

R-CHOP versus CHOP chemotherapy in older, poor-risk patients with diffuse large B-cell lymphoma

Track 6

Intergroup E4494/C9793: Maintenance rituximab versus observation after R-CHOP or CHOP in older patients with diffuse large B-cell lymphoma

Track 7

Radioimmunotherapy with tositumomab and I-131 tositumomab in diffuse large B-cell lymphoma

Track 8

LNH98-B3: Rituximab versus observation after autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma

Track 9

Phase II trial comparing two schedules of R-CHOP with bortezomib as front-line treatment for B-cell lymphoma

Head & Neck and Lung Cancers


	Edward S Kim, MD Assistant Professor of Medicine Director, Educational Programs Department of Thoracic, Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Click here to download the entire interview		MP3

Track 1

Cetuximab and weekly paclitaxel in metastatic/ recurrent head and neck squamous cell carcinoma
(H&N SCC)

Track 2

Phase II study of erlotinib, docetaxel and cisplatin in recurrent/metastatic H&N cancer

Track 3

SWOG-S0216: Docetaxel, cisplatin and fluorouracil induction followed by radiation therapy and concurrent
cisplatin for advanced H&N SCC

Track 4

pKDR/KDR ratio as a predictor of response to erlotinib and bevacizumab for recurrent or metastatic H&N cancer

Track 5

NCIC-CTG-BR20: Maintenance vandetanib in patients with small cell lung cancer (SCLC) who have a complete or partial response to induction therapy

Track 6

SWOG-S0341: Erlotinib as initial therapy for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2

Track 7

Nab paclitaxel, carboplatin and bevacizumab as first-line therapy for advanced nonsquamous NSCLC

Track 8

Weekly nab paclitaxel regimens in combination with carboplatin as first-line therapy for advanced NSCLC

Track 9

EORTC 08993-22993: Prophylactic cranial irradiation in extensive-disease SCLC


	Rogerio C Lilenbaum, MD Clinical Associate Professor of Medicine University of Miami School of Medicine Director, Thoracic Oncology Program The Mount Sinai Comprehensive Cancer Center Miami Beach, Florida Click here to download the entire interview		MP3

Track 1

BO17704: Bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent nonsquamous NSCLC

Track 2

HOG LUN 01-24/USO-023: A Phase III trial of cisplatin/etoposide in combination with concurrent radiation therapy with or without consolidation docetaxel in patients with inoperable Stage III NSCLC

Track 3

Updated analysis of SWOG-S0023: Gefitinib maintenance after definitive chemoradiation therapy followed by docetaxel in patients with locally advanced Stage III NSCLC

Track 4

Immediate versus delayed docetaxel after induction therapy with gemcitabine/carboplatin in advanced NSCLC

Track 5

Updated molecular analyses of the EGFR gene and the K-ras gene in patients with NSCLC treated with erlotinib

Track 6

Validation of a proteomic classifier for clinical benefit from erlotinib as first-line treatment for advanced NSCLC
(ECOG-3503)

Genitourinary Cancers


	Nicholas J Vogelzang, MD Director, Nevada Cancer Institute Las Vegas Professor of Medicine University of Nevada School of Medicine Las Vegas, Nevada Click here to download the entire interview		MP3

Track 1

Analysis of PSA decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC)

Track 2

EORTC-22961: Concomitant and adjuvant androgen deprivation with external beam irradiation for locally advanced prostate cancer

Track 3

Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer

Track 4

Use of a tissue biomarker panel to predict which men with a rising PSA postdefinitive prostate cancer therapy will have systemic progression

Track 5

Results of a Phase III, randomized, controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic HRPC

Track 6

Satraplatin for the treatment of HRPC

Track 7

Update of the TAX-327 study: Docetaxel with prednisone or mitoxantrone with prednisone for advanced prostate cancer

Track 8

Phase III trial of docetaxel, estramustine and prednisone versus docetaxel with prednisone in patients with metastatic HRPC

Track 9

Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer

Track 10

The impact of the duration of adjuvant hormonal therapy on patients with unfavorable-prognosis prostate cancer treated with radiation therapy: Secondary analysis of RTOG-8531


	Ronald M Bukowski, MD Director, Experimental Therapeutics Cleveland Clinic Foundation Taussig Cancer Center Professor of Medicine CCF Lerner College of Medicine of CWRU Cleveland, Ohio Click here to download the entire interview		MP3